Allogene Therapeutics (ALLO) Receivables (2020)

Allogene Therapeutics' (ALLO) quarterly Receivables came in at $3.1 million in Q3 2020, up 287.5% quarter-over-quarter from $800000.0 in Q2 2020.

Allogene Therapeutics (ALLO) Receivables (2020) Analysis & Trends

Allogene Therapeutics has disclosed Receivables across 1 years of filings, most recently posting $3.1 million for Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	13.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	2.00 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Allogene Therapeutics	482.98 Mn	482.98 Mn	-	-

Download Data